Cytomegalovirus (CMV) continues to be potentially the most important pathogen affecting organ transplant recipients. Severe gastrointestinal complications have been reported to occur in about 10% of renal transplant recipients, sometimes with dramatic presentations. We report the case of a 57-year-old CMV-seropositive woman with end-stage renal failure who developed CMV-related colonic multiple perforation 30 days after cadaveric CMV-positive renal transplantation. CMV pp65 antigenemia test and CMV-PCR had always been negative on all the weekly controls routinely performed in the postoperative period. Only after the sudden onset of this complication did the antigenemia and PCR become positive. The relationship between infection and perforation has been established beyond any doubt, as the histology of the resected colonic segment revealed florid CMV infection with evidence of typical inclusions in both macrophages and endothelial cells. Colonic perforations are often fatal in transplant recipients because of inability to contain the perforation, and only a rapid diagnosis and an aggressive surgical treatment can improve the prognosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.transproceed.2005.06.082 | DOI Listing |
BMC Surg
January 2025
Department of Anesthesiology and Intensive Care and Pain Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Background: To investigate the incidence and potential predictors of immune tolerance among adult living donor liver transplant (LDLT) recipients.
Methods: This case-control study included adult recipients who underwent LDLT between May 2004 and January 2018, with at least a 5-year follow-up after LDLT. We divided the study recipients into two groups: Group 1 (Tolerance Group) included recipients who achieved operational or prope tolerance for at least one year; Group 2 (Control Group) included recipients who did not achieve tolerance.
Transplant Proc
January 2025
Albert Einstein College of Medicine, Bronx, New York; Montefiore-Einstein Center for Transplantation, Montefiore Medical Center, Bronx, New York. Electronic address:
The foundation for OPTN policy 8.5.B that allows for en bloc kidney utilization from pediatric donors under <18 kg is unclear.
View Article and Find Full Text PDFAm J Transplant
January 2025
Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Norway; The Norwegian Renal Registry, Oslo University Hospital, Rikshospitalet, Norway.
Post-transplant lymphoproliferative disorder (PTLD) poses a serious challenge in kidney transplant recipients. Epstein-Barr virus (EBV)-seronegative recipients have a significantly increased risk of PTLD, but few studies have investigated risk factors for PTLD in EBV-seronegative recipients in the current era of immunosuppression. This cohort study from Norway and western Denmark included first-time kidney transplant recipients between 2007-2021, and estimated the cumulative incidence, risk and prognosis of PTLD.
View Article and Find Full Text PDFAm J Transplant
January 2025
Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA; Department of Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, Minnesota, USA; Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address:
The lung continuous distribution system was modified on September 27, 2023, with the goal of increasing transplant access for blood-type-O candidates after an error was discovered in the simulation used to support the development of the initial allocation policy. This retrospective observational study compares national waitlist outcomes (transplant rate, waitlist mortality) under continuous distribution before (3/10/23-9/26/23; premodification) and after (9/27/23-4/14/24; postmodification) the blood-type score modification. We fit adjusted Poisson regression models of the transplant rate and mortality rate.
View Article and Find Full Text PDFAm J Transplant
January 2025
Division of Pulmonary and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA.
Universal cytomegalovirus (CMV) prophylaxis is recommended for at-risk lung transplant recipients. Valganciclovir is currently the preferred first-line agent. Valganciclovir-related myelosuppression, however, can lead to drug discontinuation or reduction in anti-metabolite immunosuppression.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!